Study of IMC-P115C in Advanced PRAME-Positive Cancers
NCT07156136
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
140
Enrollment
INDUSTRY
Sponsor class
Conditions
PRAME Positive
Cancer
HLA-A*02:01-positive
Interventions
DRUG:
IMC-P115C
Sponsor
Immunocore Ltd